메뉴 건너뛰기




Volumn 106, Issue 8, 2014, Pages

HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

EID: 84930706705     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju212     Document Type: Editorial
Times cited : (5)

References (17)
  • 1
    • 84655162706 scopus 로고    scopus 로고
    • Treatment of HER2-positive breast cancer: Current status and future perspectives
    • Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16-32.
    • (2012) Nat Rev Clin Oncol. , vol.9 , Issue.1 , pp. 16-32
    • Arteaga, C.L.1    Sliwkowski, M.X.2    Osborne, C.K.3
  • 2
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283.
    • (2011) N Engl J Med. , vol.365 , Issue.14 , pp. 1273-1283
    • Slamon, D.1    Eiermann, W.2    Robert, N.3
  • 3
    • 84855297353 scopus 로고    scopus 로고
    • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial
    • Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
    • (2012) Lancet Oncol. , vol.13 , Issue.1 , pp. 25-32
    • Gianni, L.1    Pienkowski, T.2    Im, Y.H.3
  • 4
    • 84862893473 scopus 로고    scopus 로고
    • Pathological complete response and accelerated drug approval in early breast cancer
    • Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med. 2012;366(26):2438-2441.
    • (2012) N Engl J Med. , vol.366 , Issue.26 , pp. 2438-2441
    • Prowell, T.M.1    Pazdur, R.2
  • 5
    • 84899465847 scopus 로고    scopus 로고
    • A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Abstract S1-04
    • San Antonio, Texas: Cancer Resarch Abstract 73
    • Tolaney SM, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) Abstract S1-04. In: San Antonio Breast Cancer Symposium. San Antonio, Texas: Cancer Resarch; 2013. Abstract 73.
    • (2013) San Antonio Breast Cancer Symposium
    • Tolaney, S.M.1    Barry, W.T.2    Dang, C.T.3
  • 6
    • 84655169981 scopus 로고    scopus 로고
    • Practical implications of gene-expressionbased assays for breast oncologists
    • Prat A, Ellis MJ, Perou CM. Practical implications of gene-expressionbased assays for breast oncologists. Nat Rev Clin Oncol. 2012;9(1):48-57.
    • (2012) Nat Rev Clin Oncol. , vol.9 , Issue.1 , pp. 48-57
    • Prat, A.1    Ellis, M.J.2    Perou, C.M.3
  • 7
    • 84930718892 scopus 로고    scopus 로고
    • Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer
    • press
    • Prat A, Carey JA, Adamo B, et al. Molecular Features and Survival Outcomes of the Intrinsic Subtypes within HER2-Positive Breast Cancer. J Natl Cancer Inst. 2014;in press.
    • (2014) J Natl Cancer Inst.
    • Prat, A.1    Carey, J.A.2    Adamo, B.3
  • 8
    • 62449131093 scopus 로고    scopus 로고
    • Supervised risk predictor of breast cancer based on intrinsic subtypes
    • Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167.
    • (2009) J Clin Oncol. , vol.27 , Issue.8 , pp. 1160-1167
    • Parker, J.S.1    Mullins, M.2    Cheang, M.C.3
  • 9
    • 84905920752 scopus 로고    scopus 로고
    • First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) In: ASCO. Chicago, IL
    • Abstract LBA4
    • Piccart-Gebhart MJ, Holmes AP, Baselga J, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC) In: ASCO. Chicago, IL: J Clin Oncol; 2014. Abstract LBA4.
    • (2014) J Clin Oncol
    • Piccart-Gebhart, M.J.1    Holmes, A.P.2    Baselga, J.3
  • 10
    • 0035884620 scopus 로고    scopus 로고
    • Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial
    • Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19(18):3808-3816.
    • (2001) J Clin Oncol. , vol.19 , Issue.18 , pp. 3808-3816
    • Ellis, M.J.1    Coop, A.2    Singh, B.3
  • 11
    • 84859839286 scopus 로고    scopus 로고
    • Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial
    • Cheang MC, Voduc KD, Tu D, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res. 2012;18(8):2402-2412.
    • (2012) Clin Cancer Res. , vol.18 , Issue.8 , pp. 2402-2412
    • Cheang, M.C.1    Voduc, K.D.2    Tu, D.3
  • 12
    • 84923179170 scopus 로고    scopus 로고
    • Gene expression signatures in preand post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). In: ASCO. Chicago, IL
    • Abstract 506
    • Carey LA, Barry WT, Pitcher B, et al. Gene expression signatures in preand post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). In: ASCO. Chicago, IL: J Clin Oncol; 2014. Abstract 506.
    • (2014) Clin Oncol
    • Carey, L.A.1    Barry, W.T.2    Pitcher, B.3
  • 13
    • 84872847361 scopus 로고    scopus 로고
    • The genomic landscape of breast cancer as a therapeutic roadmap
    • Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013;3(1):27-34.
    • (2013) Cancer Discov. , vol.3 , Issue.1 , pp. 27-34
    • Ellis, M.J.1    Perou, C.M.2
  • 14
    • 84896723087 scopus 로고    scopus 로고
    • Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstact S5-01
    • San Antonio, Texas: Cancer Research Abstract 73
    • Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Abstact S5-01. In: San Antonio Breast Cancer Symposium. San Antonio, Texas: Cancer Research; 2013. Abstract 73.
    • (2013) San Antonio Breast Cancer Symposium
    • Sikov, W.M.1    Berry, D.A.2    Perou, C.M.3
  • 15
    • 35148885729 scopus 로고    scopus 로고
    • A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    • Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
    • (2007) Cancer Cell. , vol.12 , Issue.4 , pp. 395-402
    • Berns, K.1    Horlings, H.M.2    Hennessy, B.T.3
  • 16
    • 79959268722 scopus 로고    scopus 로고
    • Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031
    • Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
    • (2011) J Clin Oncol. , vol.29 , Issue.17 , pp. 2342-2349
    • Ellis, M.J.1    Suman, V.J.2    Hoog, J.3
  • 17
    • 84861527388 scopus 로고    scopus 로고
    • The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
    • Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
    • (2012) Nature , vol.486 , Issue.7403 , pp. 346-352
    • Curtis, C.1    Shah, S.P.2    Chin, S.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.